ATE87005T1 - Hydroxamsaeuren. - Google Patents

Hydroxamsaeuren.

Info

Publication number
ATE87005T1
ATE87005T1 AT87300366T AT87300366T ATE87005T1 AT E87005 T1 ATE87005 T1 AT E87005T1 AT 87300366 T AT87300366 T AT 87300366T AT 87300366 T AT87300366 T AT 87300366T AT E87005 T1 ATE87005 T1 AT E87005T1
Authority
AT
Austria
Prior art keywords
hydroxamic acids
acids
formula
amino acid
acid residue
Prior art date
Application number
AT87300366T
Other languages
German (de)
English (en)
Inventor
Andrew Shaw
Donald John Wolanin
Original Assignee
Ici America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici America Inc filed Critical Ici America Inc
Application granted granted Critical
Publication of ATE87005T1 publication Critical patent/ATE87005T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87300366T 1986-01-21 1987-01-16 Hydroxamsaeuren. ATE87005T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868601368A GB8601368D0 (en) 1986-01-21 1986-01-21 Hydroxamic acids
EP87300366A EP0231081B1 (en) 1986-01-21 1987-01-16 Hydroxamic acids

Publications (1)

Publication Number Publication Date
ATE87005T1 true ATE87005T1 (de) 1993-04-15

Family

ID=10591684

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87300366T ATE87005T1 (de) 1986-01-21 1987-01-16 Hydroxamsaeuren.

Country Status (7)

Country Link
EP (1) EP0231081B1 (OSRAM)
JP (1) JP2532859B2 (OSRAM)
AT (1) ATE87005T1 (OSRAM)
DE (1) DE3784743T2 (OSRAM)
ES (1) ES2053525T3 (OSRAM)
GB (1) GB8601368D0 (OSRAM)
GR (1) GR3007389T3 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455818A4 (en) * 1989-11-24 1993-05-12 Banyu Pharmaceutical Co., Ltd. Physiologically active substance be-16627
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9213473D0 (en) * 1992-06-25 1992-08-12 Hoffmann La Roche Hydroxamic acid derivatives
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
DK0927168T3 (da) * 1996-08-28 2003-03-10 Procter & Gamble 1,3-diheterocykliske metalloproteaseinhibitorer
EP0927183B1 (en) * 1996-08-28 2004-07-28 THE PROCTER & GAMBLE COMPANY Spirocyclic metalloprotease inhibitors
NZ334254A (en) 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
RU2170232C2 (ru) * 1996-08-28 2001-07-10 Дзе Проктер Энд Гэмбл Компани Амиды фосфиновых кислот и способ предупреждения или лечения заболевания, связанного с нежелательной активностью металлопротеазы
SK25199A3 (en) * 1996-08-28 2000-02-14 Procter & Gamble Heterocyclic metalloprotease inhibitors
NZ333923A (en) 1996-09-10 2000-11-24 British Biotech Pharm Cytostatic hydroxamic acid derivatives for inhibiting proliferation of tumour cells
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
HUP0004595A3 (en) 1997-07-31 2001-12-28 Procter & Gamble Acyclic metalloprotease inhibitors
IL145089A0 (en) 1999-03-03 2002-06-30 Procter & Gamble Alkenyl-and alkynyl-containing metalloprotease inhibitors
WO2002006227A1 (en) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors

Also Published As

Publication number Publication date
EP0231081B1 (en) 1993-03-17
ES2053525T3 (es) 1994-08-01
EP0231081A2 (en) 1987-08-05
JP2532859B2 (ja) 1996-09-11
GB8601368D0 (en) 1986-02-26
EP0231081A3 (en) 1989-11-15
JPS62228097A (ja) 1987-10-06
DE3784743D1 (en) 1993-04-22
GR3007389T3 (OSRAM) 1993-07-30
DE3784743T2 (de) 1993-06-24

Similar Documents

Publication Publication Date Title
ES2053525T3 (es) Acidos hidroxamicos.
DZ1405A1 (fr) Dérivés de n-(3-hydroxy-4-piperidinyl)(dihydro-benzofuranne, dihydro-2h-benzopy-ranne ou dishydro-benzodioxin)carboxamide.
NL300283I1 (nl) Alfa- en bèta-aminozuur-hydroxyethylamino-sulfonamiden die toepasbaar zijn als retrovirale-prothease-remmers.
FI850078A0 (fi) N-(4-piperidinyl)-bicykliska -kondenserade 2-imidazolaminderivat.
BR9305162A (pt) Composto, formulação farmacêutica e processo para a preparação de um composto
LV5738A4 (lv) Aminoskabju atvasinajumi
DK0412404T3 (da) Thiazolderivater, fremgangsmåder til fremstilling deraf og farmaceutiske præparater omfattende derivaterne
NO884208D0 (no) Substituerte n-(1-alkyl-3-hydroksy-4-piperidinyl) benzamider.
BR9305164A (pt) Composto, formulação farmacêutica e processo para preparar um composto
NO894349L (no) Tienopyridin-type mevalonolaktoner.
AU590172B2 (en) Various N-substituted 3-piperidine carboxylic acids or N-substituted 3-pyridinecarboxylic acids and derivatives thereof
ATE48001T1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate.
FR2558837B1 (fr) Derives de l'acide methylenediphosphonique, procede d'obtention et medicaments antirhumatismaux les contenant
AU3895689A (en) Cyclic sulfur-containing amino acid derivatives
PH21632A (en) Process for preparing n-substituted amido amino acid
ES2054989T3 (es) Derivados de aminodiol inhibidores de renina.
ZA9610804B (en) 4-Imidazolidinone compound process for its preparation and the pharmaceutical compositions which contain it
DE3587915D1 (de) Verfahren zur Herstellung von Cephalosporinen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time